Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $9.40 billion. The enterprise value is $7.60 billion.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 128.76 million shares outstanding. The number of shares has increased by 25.57% in one year.
| Current Share Class | 128.76M |
| Shares Outstanding | 128.76M |
| Shares Change (YoY) | +25.57% |
| Shares Change (QoQ) | +9.30% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 103.95% |
| Float | 119.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.77 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.75, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.75 |
| Quick Ratio | 12.61 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.41% and return on invested capital (ROIC) is -15.32%.
| Return on Equity (ROE) | -20.41% |
| Return on Assets (ROA) | -14.47% |
| Return on Invested Capital (ROIC) | -15.32% |
| Return on Capital Employed (ROCE) | -16.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 414 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.96% in the last 52 weeks. The beta is 1.02, so Vaxcyte's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +1.96% |
| 50-Day Moving Average | 82.38 |
| 200-Day Moving Average | 89.11 |
| Relative Strength Index (RSI) | 40.78 |
| Average Volume (20 Days) | 1,264,673 |
Short Selling Information
The latest short interest is 13.33 million, so 10.36% of the outstanding shares have been sold short.
| Short Interest | 13.33M |
| Short Previous Month | 13.53M |
| Short % of Shares Out | 10.36% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 11.56 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -569.55M |
| Pretax Income | -497.19M |
| Net Income | -463.93M |
| EBITDA | -562.54M |
| EBIT | -569.55M |
| Earnings Per Share (EPS) | -$3.80 |
Full Income StatementBalance Sheet
The company has $1.75 billion in cash and $71.11 million in debt, giving a net cash position of $1.68 billion or $13.02 per share.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | 71.11M |
| Net Cash | 1.68B |
| Net Cash Per Share | $13.02 |
| Equity (Book Value) | 3.31B |
| Book Value Per Share | 26.47 |
| Working Capital | 1.65B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$452.63 million and capital expenditures -$119.16 million, giving a free cash flow of -$571.79 million.
| Operating Cash Flow | -452.63M |
| Capital Expenditures | -119.16M |
| Free Cash Flow | -571.79M |
| FCF Per Share | -$4.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |